低剂量脑衍生神经营养因子 (BDNF) 对心房复发的影响
Massimo Fioranelli1, Luigi Spadafora2, Marco Bernardi3
1Department of Human Sciences, Guglielmo Marconi University, Rome, Italy.
Minerva cardiology and angiology
|June 20, 2023
概括
低剂量脑衍生神经营养因子 (BDNF) 治疗在没有结构性心脏病的患者中显著降低了心房的发作. 这种疗法在70岁以上的人群中表现出特别高的有效性,这表明了潜在的新治疗途径.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心房动 (AF) 是一种普遍的心律失常,与高发病率和死亡率有关.
- 导管切除是有效的,但存在并发症和复发的风险.
- 大脑衍生神经营养因子 (BDNF) 正在被探索,因为它有潜力减轻心脏动 (PAF).
研究的目的:
- 评估低剂量BDNF对减少心脏动发作 (PAF) 的影响.
- 评估BDNF在患有PAF且没有结构性心脏病的患者中的疗效.
主要方法:
- 一项涉及22名被诊断患有PAF且没有结构性心脏病的患者的研究.
- 在24个月内每天服用20滴GUNA-BDNF.
- 通过PAF发作的平均月度持续时间来测量心律失常负担.
主要成果:
- 每月PAF平均持续时间从65.3分钟大幅减少到9.5分钟 (P<0.001).
- 在22名患者中,有17名患者经历了节律失常负担的消除或显著减少.
- 在70岁及以上的患者中观察到更大的疗效.
结论:
- 低剂量的BDNF疗法在减少AF负担和复发方面发挥了重要作用.
- 在70岁以上没有结构性心脏病的患者中,效果特别明显.
- 需要进一步的临床和分子研究来确定BDNF作为PAF治疗方法.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...


